Phase II Clinical Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B-cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma (Multicenter, Open-label).

Trial Profile

Phase II Clinical Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B-cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma (Multicenter, Open-label).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab
  • Indications B cell lymphoma; Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors SymBio Pharmaceuticals
  • Most Recent Events

    • 01 Apr 2017 Results published in the International Journal of Hematology
    • 07 Jun 2016 Results assessing efficacy and safety, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 10 Feb 2015 According to a media release, SymBio Pharmaceuticals is planning to file the sNDA in Japan, following the decision for marketing approval by Federal Institute for Drugs and Medical Devices in Europe.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top